B lymphocytes are capable of modulating the release of pro-inflammatory cytokines such as IL-1β, TNF, and IL-18 through the release of CD20 antibody or B cell activating factor (BAFF), subsequently reducing the systemic inflammatory response, diminishing myocardial infarction size, and enhancing cardiac function post-myocardial infarction [56]. This evidence concerns the gene TNFSF13B and myocardial infarction.